Compare DNN & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DNN | IBRX |
|---|---|---|
| Founded | 1954 | 2014 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.3B |
| IPO Year | 1997 | N/A |
| Metric | DNN | IBRX |
|---|---|---|
| Price | $2.57 | $2.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $9.71 |
| AVG Volume (30 Days) | ★ 47.1M | 12.6M |
| Earning Date | 11-06-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $3,493,456.00 | ★ $82,555,000.00 |
| Revenue This Year | $197.29 | $667.18 |
| Revenue Next Year | $55.12 | $88.32 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 23.35 | ★ 1025.95 |
| 52 Week Low | $1.08 | $1.83 |
| 52 Week High | $3.42 | $4.27 |
| Indicator | DNN | IBRX |
|---|---|---|
| Relative Strength Index (RSI) | 47.59 | 43.96 |
| Support Level | $2.48 | $2.06 |
| Resistance Level | $2.64 | $2.50 |
| Average True Range (ATR) | 0.14 | 0.15 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 25.00 | 6.82 |
Denison Mines Corp is a uranium exploration and development company focused on the Athabasca Basin region of northern Saskatchewan, Canada. The company holds a noteworthy 95% interest in its flagship Wheeler River Uranium Project, the undeveloped uranium project located in the infrastructure-rich eastern part of the Athabasca Basin. Additionally, it is involved in mine decommissioning and environmental services through its Closed Mines group, which manages the Elliot Lake reclamation projects and offers third-party post-closure mine care and maintenance services. The Company operates in two main segments: the Mining segment and the Corporate and Other segment. The majority of revenue is generated from the mining segment.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.